Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP): gonorrhoea treatment optimization, 2024 report
Overview
The WHO Enhanced Gonococcal Antimicrobial Surveillance Programme (EGASP) monitors Neisseria gonorrhoeae antimicrobial resistance to guide treatment optimization. It aligns with the WHO Global Action Plan on AMR and the Global Antimicrobial Resistance and Use Surveillance System (GLASS), providing quality-assured data to inform global and national guidelines.
The first EGASP report (data from 2015–2022) covered 4 countries, while the 2024 report (data of 2023) expanded to 9, showing rising resistance to key treatments such as ceftriaxone and azithromycin. EGASP operates through sentinel sites with WHO technical support, building national capacity for sexually transmitted infections (STI) surveillance and laboratory skills. In the current report (data of 2024), 13 countries across 5 WHO regions participated, with the latest figures including demographic, clinical, and antimicrobial resistance data.
